AstraZeneca’s Triple Combination Regimen Receives NMPA’s Approval as the Maintenance Treatment for COPD in China

 AstraZeneca’s Triple Combination Regimen Receives NMPA’s Approval as the Maintenance Treatment for COPD in China

AstraZeneca’s Triple Combination Regimen Receives NMPA’s Approval as the Maintenance Treatment for COPD in China

Shots:

  • The approval follows PR designation and is based on P-III KRONOS study assessing budesonide/glycopyrronium/formoterol fumarate vs Bevespi Aerosphere (glycopyrronium/formoterol fumarate) and PT009 (budesonide/formoterol fumarate, demonstrated significant improvement in FEV1
  • The approval marks the first NMPA approval for a fixed-dose triple-combination regimen in a pressurized metered-dose inhaler device which utilizes Aerosphere delivery technology
  • Breztri Aerosphere is an approved triple combination therapy in Japan and is under regulatory review in the US & EU. The triple combination regimen is k/a PT010 outside of China

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: The Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post